Q2 2024 Earnings Estimate for Zimmer Biomet Holdings, Inc. Issued By Zacks Research (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) – Zacks Research reduced their Q2 2024 earnings estimates for shares of Zimmer Biomet in a research report issued to clients and investors on Thursday, May 23rd. Zacks Research analyst U. Biswas now forecasts that the medical equipment provider will earn $1.95 per share for the quarter, down from their prior estimate of $2.00. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.10 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q1 2025 earnings at $2.06 EPS, Q2 2025 earnings at $2.15 EPS and FY2025 earnings at $8.66 EPS.

Zimmer Biomet (NYSE:ZBHGet Free Report) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.07. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.89 EPS.

A number of other analysts also recently weighed in on ZBH. Oppenheimer increased their target price on shares of Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Citigroup increased their price target on Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Barclays increased their price target on Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a report on Monday, February 12th. Royal Bank of Canada restated an “outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, May 17th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $134.40.

Check Out Our Latest Analysis on Zimmer Biomet

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $116.41 on Monday. The company has a market capitalization of $23.95 billion, a PE ratio of 25.20, a P/E/G ratio of 2.10 and a beta of 1.03. The company has a 50 day simple moving average of $123.26 and a two-hundred day simple moving average of $121.82. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. Zimmer Biomet has a fifty-two week low of $102.00 and a fifty-two week high of $147.50.

Hedge Funds Weigh In On Zimmer Biomet

Several large investors have recently bought and sold shares of the stock. OLD Point Trust & Financial Services N A purchased a new stake in shares of Zimmer Biomet during the 4th quarter valued at $26,000. Crewe Advisors LLC purchased a new stake in shares of Zimmer Biomet during the 1st quarter valued at $31,000. Ables Iannone Moore & Associates Inc. purchased a new stake in shares of Zimmer Biomet during the 4th quarter valued at $30,000. J.Safra Asset Management Corp increased its position in shares of Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 235 shares during the last quarter. Finally, Naples Money Management LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter valued at $35,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.82%. The ex-dividend date of this dividend is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Read More

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.